Edizioni

Rivista e Edizione

AHEAD OF PRINT

Volume 60 (2022): Edizione 3 (September 2022)

Volume 60 (2022): Edizione 2 (June 2022)

Volume 60 (2022): Edizione 1 (March 2022)

Volume 59 (2021): Edizione 4 (December 2021)

Volume 59 (2021): Edizione 3 (September 2021)

Volume 59 (2021): Edizione 2 (June 2021)

Volume 59 (2021): Edizione 1 (March 2021)

Volume 58 (2020): Edizione 4 (December 2020)

Volume 58 (2020): Edizione 3 (September 2020)

Volume 58 (2020): Edizione 2 (June 2020)

Volume 58 (2020): Edizione 1 (March 2020)

Volume 57 (2019): Edizione 4 (December 2019)

Volume 57 (2019): Edizione 3 (September 2019)

Volume 57 (2019): Edizione 2 (June 2019)

Volume 57 (2019): Edizione 1 (March 2019)

Volume 56 (2018): Edizione 4 (December 2018)

Volume 56 (2018): Edizione 3 (September 2018)

Volume 56 (2018): Edizione 2 (June 2018)

Volume 56 (2018): Edizione 1 (March 2018)

Volume 55 (2017): Edizione 4 (December 2017)

Volume 55 (2017): Edizione 3 (September 2017)

Volume 55 (2017): Edizione 2 (June 2017)

Volume 55 (2017): Edizione 1 (March 2017)

Volume 54 (2016): Edizione 4 (December 2016)

Volume 54 (2016): Edizione 3 (September 2016)

Volume 54 (2016): Edizione 2 (June 2016)

Volume 54 (2016): Edizione 1 (March 2016)

Volume 53 (2015): Edizione 4 (December 2015)

Volume 53 (2015): Edizione 3 (September 2015)

Volume 53 (2015): Edizione 2 (June 2015)

Volume 53 (2015): Edizione 1 (March 2015)

Dettagli della rivista
Formato
Rivista
eISSN
2501-062X
Pubblicato per la prima volta
30 Mar 2015
Periodo di pubblicazione
4 volte all'anno
Lingue
Inglese

Cerca

AHEAD OF PRINT

Dettagli della rivista
Formato
Rivista
eISSN
2501-062X
Pubblicato per la prima volta
30 Mar 2015
Periodo di pubblicazione
4 volte all'anno
Lingue
Inglese

Cerca

5 Articoli
access type Accesso libero

Comparison of Salivary Interleukin-6, Interleukin-8, C - reactive protein levels and Total Antioxidants Capacity of Obese Individuals with Normal Weight Ones

Pubblicato online: 17 Aug 2022
Pagine: -

Astratto

Abstract

Objective: Obesity is a worldwide concern that may lead in type 2 diabetes, cardiovascular diseases, etc. Several serum biomarkers have been identified in the saliva of obese individuals, including inflammatory cytokines, adipokines, insulin, and cortisol. The present study aimed to compare salivary interleukin-6(IL-6), interleukin-8(IL-8), C-reactive protein (CRP) levels and total antioxidants capacity (TAC) of obese individuals with normal-weighted ones.

Methods: In this case–control study, 92 participants matched in terms of age and gender were placed into two groups according to the body mass index (BMI); case group: BMI>30 and control group: 18.5<BMI<24.99. Unstimulated saliva was collected. ELISA and FRAP method were used to determine IL-6, IL-8, CRP and TAC. Data was analyzed using SPSS 24, at the significant level of 0.05.

Results: Mean salivary levels of IL-6 and IL-8 in the normal individuals were 53.36 and 421.25ng/mL, with 86.09ng/mL and 510.19ng/mL in obese individuals, respectively. There were significant differences in the mean salivary levels of IL-6 and IL-8 between two experimental groups.

The mean salivary levels of CRP of control and case group was 2.84 and2.63 ng/mL and the total salivary antioxidant levels in the normal and obese individuals were 0.29 and 0.36, respectively which had no significant different.

Conclusion: According to the results of the present study, salivary levels IL-8 and IL-6 was significantly higher in obese individuals than in those with normal weight. However, the mean salivary CRP and TAC were not significantly different between the obese individuals and normal-weighted ones.

Parole chiave

  • obesity
  • C-reactive protein
  • interleukin-6
  • interleukin-8
  • antioxidants
  • Saliva
  • obesity markers
access type Accesso libero

The Role of Tei Index added to the GRACE risk score for prediction of in-hospital MACE after acute myocardial infarction

Pubblicato online: 17 Aug 2022
Pagine: -

Astratto

Abstract

Introduction: The Global Registry of Acute Coronary Events (GRACE) risk score is widely recommended for risk assessment in patients with acute myocardial infarction (AMI). Variable degrees of impairment in left ventricular (LV) systolic and diastolic function might be found after AMI. Tei Index is an echocardiography parameter that represents both systolic and diastolic LV performance. Previous studies demonstrate Tei Index as an independent predictor of Major Adverse Cardiovascular Events (MACE) after AMI. This study investigates whether the addition of Tei Index could improve the GRACE risk score performance to predict inhospital MACE after AMI.

Methods: A prospective cohort study was conducted on 75 patients who presented with AMI. Total GRACE score was calculated on patient admission and echocardiography was conducted within 72 hours of hospitalization for measurement of MPI. All patients were observed for the incidence of MACE during hospitalization. The incremental predictive value of the GRACE risk score alone and combined with Tei Index was assessed by the change in area under the curve (AUC) by DeLong’s method, likelihood ratio test (LRT), and continuous net reclassification improvement (cNRI).

Results: The addition of Tei Index to the GRACE risk score significantly improves the predictive value of the GRACE risk score (increase in AUC from 0.753 for the GRACE risk score to 0.801 for the GRACE score combine with Tei Index, p=0.354; LRT=4.65, p=0.030; cNRI=0.515, p=0.046).

Conclusions: Adjustment of Tei Index to GRACE risk score might improve risk prediction of in-hospital MACE after AMI.

Parole chiave

  • acute myocardial infarction
  • myocardial dysfunction
  • GRACE
  • MACE
  • Tei Index
  • risk score
access type Accesso libero

Comparison of scoring systems for predicting remission of Type 2 diabetes in sleeve gastrectomy patients

Pubblicato online: 25 Sep 2022
Pagine: -

Astratto

Abstract

Introduction: This study aims to compare the predictive capacity of ABCD, DiaRem2, Ad-DiaRem, and DiaBetter scoring systems for type 2 diabetes mellitus (T2DM) remission in Turkish adult morbidly obese patients who underwent SG.

Methods: This retrospective cohort study included 80 patients who underwent sleeve gastrectomy (SG) operation, were diagnosed with T2DM preoperatively, and had at least one-year follow-up after surgery. Because bariatric surgery is performed on patients with class III obesity (BMI ≥ 40 kg/m2) or class II obesity (BMI ≥ 35 kg/m2) with obesity releated comorbid conditions in our hospital, our study cohort consisted of these patients.

Results: The diagnostic performance of the DiaBetter, DiaRem2, Ad-DiaRem and ABCD for identifying diabetes remission, assessed by the AUC was 0.882 (95% CI, 0.807-0.958, p < 0.001), 0.862 (95% CI, 0.779-0.945, p < 0.001), 0.849 (95% CI, 0.766-0.932, p < 0.001) and 0.726 (95% CI, 0.601-0.851, p = 0.002), respectively. The AUCs of the Ad-Diarem, DiaBetter and DiaRem2 were statistically higher than AUC of the ABCD (all p-value < 0.001). Besides, there was no statistically significant difference in AUCs of the Ad-Diarem, DiaBetter and DiaRem scores (all p-value > 0.05).

Conclusion: Ad-Dairem, DiaBetter and DaiRem scoring systems were found to provide a successful prediction for diabetes remission in sleeve gastrectomy patients. It was observed that the predictive power of the ABCD scoring system was lower than the other systems. We think that the use of scoring systems for diabetes remission, which have a simple use, will become widespread.

Parole chiave

  • bariatric surgery
  • sleeve gastrectomy
  • Type 2 diabetes
  • diabetes remission
  • ABCD score
access type Accesso libero

Association between serum midkine levels and tumor size in Indonesian hepatocellular carcinoma patients: a cross-sectional study

Pubblicato online: 25 Sep 2022
Pagine: -

Astratto

Abstract

Background: The incidence of liver cancer is increased worldwide with 75%–85% are diagnosed as hepatocellular carcinoma (HCC). Current practice has low sensitivity limitations to diagnose the early stages of HCC, thus urging the need for a biomarker with higher sensitivity to detect HCC, specifically in the early stage. This study aimed to determine the association between Midkine levels and progressiveness of hepatocellular carcinoma (HCC), according to tumor size, Barcelona Clinic Liver Cancer (BCLC), and presence of portal venous thrombosis.

Methods: This cross-sectional study involved 100 patients in Adam Malik General Hospital diagnosed with HCC, collected with a consecutive sampling method, whose diagnosis were confirmed by findings of hypervascular on arterial phase imaging and portal vein or delayed phase washout triple-phase CT Scan. Samples are later categorized according to Barcelona Clinic Liver Cancer (BCLC) stages, tumor size, and presence of portal venous thrombosis. Blood samples were drawn to measure serum Midkine using ELISA. Kruskal-Wallis and Mann-Whitney U tests were conducted to determine the difference of Midkine levels based on tumor size, BCLC staging, and presence of portal venous thrombosis.

Results: Serum Midkine level shows a significant difference over tumor size (p=0.014), no significant difference found compared to BCLC stages and presence of portal venous thrombosis.

Conclusion: Serum Midkine levels are associated with the tumor size of HCC, thus helping physicians determine treatment plans.

Parole chiave

  • Midkine
  • liver neoplasms
  • hepatocellular carcinoma
  • biomarker
  • cytokine
access type Accesso libero

External Validation of the 4C Mortality Score and PRIEST COVID-19 Clinical Severity Score in patients hospitalized with COVID-19 pneumonia in Greece

Pubblicato online: 25 Sep 2022
Pagine: -

Astratto

Abstract

Background: Prognostic scores can be used to facilitate better management of patients suffering from life-threatening diseases, provided that they have been tested in the population of interest.

Aim: To perform external validation of the 4C Mortality Score and PRIEST COVID-19 Clinical Severity Score.

Study Design: Prospective Observational Study.

Methods: Patients hospitalized with COVID-19 pneumonia in a tertiary hospital in Greece were enrolled in the study. The prognostic scores were calculated based on hospital admission data and ROC curve analysis was performed. We assessed a composite outcome of either in-hospital death or need for invasive ventilation.

Results: Both 4C and PRIEST scores showed good discriminative ability with an AUC value of 0.826 (CI 95%: 0.765-0.887) and 0.852 (CI 95%: 0.793-0.910) respectively. Based on the Youden Index the optimal cut-off for the 4C score was 11 (Sensitivity 75%, Specificity 75.5%) and 10 for the PRIEST score (Sensitivity 83% and Specificity 69.4%). Calibration was adequate for both scores, except for the low and very high risk groups in the PRIEST score.

Conclusion: The 4C Mortality Score and PRIEST COVID-19 Clinical Severity Score can be used for early identification of patients with poor prognosis in a Greek population cohort hospitalized with COVID-19.

Parole chiave

  • prognosis
  • risk scores
  • covid-19
  • triage
  • risk assessment
5 Articoli
access type Accesso libero

Comparison of Salivary Interleukin-6, Interleukin-8, C - reactive protein levels and Total Antioxidants Capacity of Obese Individuals with Normal Weight Ones

Pubblicato online: 17 Aug 2022
Pagine: -

Astratto

Abstract

Objective: Obesity is a worldwide concern that may lead in type 2 diabetes, cardiovascular diseases, etc. Several serum biomarkers have been identified in the saliva of obese individuals, including inflammatory cytokines, adipokines, insulin, and cortisol. The present study aimed to compare salivary interleukin-6(IL-6), interleukin-8(IL-8), C-reactive protein (CRP) levels and total antioxidants capacity (TAC) of obese individuals with normal-weighted ones.

Methods: In this case–control study, 92 participants matched in terms of age and gender were placed into two groups according to the body mass index (BMI); case group: BMI>30 and control group: 18.5<BMI<24.99. Unstimulated saliva was collected. ELISA and FRAP method were used to determine IL-6, IL-8, CRP and TAC. Data was analyzed using SPSS 24, at the significant level of 0.05.

Results: Mean salivary levels of IL-6 and IL-8 in the normal individuals were 53.36 and 421.25ng/mL, with 86.09ng/mL and 510.19ng/mL in obese individuals, respectively. There were significant differences in the mean salivary levels of IL-6 and IL-8 between two experimental groups.

The mean salivary levels of CRP of control and case group was 2.84 and2.63 ng/mL and the total salivary antioxidant levels in the normal and obese individuals were 0.29 and 0.36, respectively which had no significant different.

Conclusion: According to the results of the present study, salivary levels IL-8 and IL-6 was significantly higher in obese individuals than in those with normal weight. However, the mean salivary CRP and TAC were not significantly different between the obese individuals and normal-weighted ones.

Parole chiave

  • obesity
  • C-reactive protein
  • interleukin-6
  • interleukin-8
  • antioxidants
  • Saliva
  • obesity markers
access type Accesso libero

The Role of Tei Index added to the GRACE risk score for prediction of in-hospital MACE after acute myocardial infarction

Pubblicato online: 17 Aug 2022
Pagine: -

Astratto

Abstract

Introduction: The Global Registry of Acute Coronary Events (GRACE) risk score is widely recommended for risk assessment in patients with acute myocardial infarction (AMI). Variable degrees of impairment in left ventricular (LV) systolic and diastolic function might be found after AMI. Tei Index is an echocardiography parameter that represents both systolic and diastolic LV performance. Previous studies demonstrate Tei Index as an independent predictor of Major Adverse Cardiovascular Events (MACE) after AMI. This study investigates whether the addition of Tei Index could improve the GRACE risk score performance to predict inhospital MACE after AMI.

Methods: A prospective cohort study was conducted on 75 patients who presented with AMI. Total GRACE score was calculated on patient admission and echocardiography was conducted within 72 hours of hospitalization for measurement of MPI. All patients were observed for the incidence of MACE during hospitalization. The incremental predictive value of the GRACE risk score alone and combined with Tei Index was assessed by the change in area under the curve (AUC) by DeLong’s method, likelihood ratio test (LRT), and continuous net reclassification improvement (cNRI).

Results: The addition of Tei Index to the GRACE risk score significantly improves the predictive value of the GRACE risk score (increase in AUC from 0.753 for the GRACE risk score to 0.801 for the GRACE score combine with Tei Index, p=0.354; LRT=4.65, p=0.030; cNRI=0.515, p=0.046).

Conclusions: Adjustment of Tei Index to GRACE risk score might improve risk prediction of in-hospital MACE after AMI.

Parole chiave

  • acute myocardial infarction
  • myocardial dysfunction
  • GRACE
  • MACE
  • Tei Index
  • risk score
access type Accesso libero

Comparison of scoring systems for predicting remission of Type 2 diabetes in sleeve gastrectomy patients

Pubblicato online: 25 Sep 2022
Pagine: -

Astratto

Abstract

Introduction: This study aims to compare the predictive capacity of ABCD, DiaRem2, Ad-DiaRem, and DiaBetter scoring systems for type 2 diabetes mellitus (T2DM) remission in Turkish adult morbidly obese patients who underwent SG.

Methods: This retrospective cohort study included 80 patients who underwent sleeve gastrectomy (SG) operation, were diagnosed with T2DM preoperatively, and had at least one-year follow-up after surgery. Because bariatric surgery is performed on patients with class III obesity (BMI ≥ 40 kg/m2) or class II obesity (BMI ≥ 35 kg/m2) with obesity releated comorbid conditions in our hospital, our study cohort consisted of these patients.

Results: The diagnostic performance of the DiaBetter, DiaRem2, Ad-DiaRem and ABCD for identifying diabetes remission, assessed by the AUC was 0.882 (95% CI, 0.807-0.958, p < 0.001), 0.862 (95% CI, 0.779-0.945, p < 0.001), 0.849 (95% CI, 0.766-0.932, p < 0.001) and 0.726 (95% CI, 0.601-0.851, p = 0.002), respectively. The AUCs of the Ad-Diarem, DiaBetter and DiaRem2 were statistically higher than AUC of the ABCD (all p-value < 0.001). Besides, there was no statistically significant difference in AUCs of the Ad-Diarem, DiaBetter and DiaRem scores (all p-value > 0.05).

Conclusion: Ad-Dairem, DiaBetter and DaiRem scoring systems were found to provide a successful prediction for diabetes remission in sleeve gastrectomy patients. It was observed that the predictive power of the ABCD scoring system was lower than the other systems. We think that the use of scoring systems for diabetes remission, which have a simple use, will become widespread.

Parole chiave

  • bariatric surgery
  • sleeve gastrectomy
  • Type 2 diabetes
  • diabetes remission
  • ABCD score
access type Accesso libero

Association between serum midkine levels and tumor size in Indonesian hepatocellular carcinoma patients: a cross-sectional study

Pubblicato online: 25 Sep 2022
Pagine: -

Astratto

Abstract

Background: The incidence of liver cancer is increased worldwide with 75%–85% are diagnosed as hepatocellular carcinoma (HCC). Current practice has low sensitivity limitations to diagnose the early stages of HCC, thus urging the need for a biomarker with higher sensitivity to detect HCC, specifically in the early stage. This study aimed to determine the association between Midkine levels and progressiveness of hepatocellular carcinoma (HCC), according to tumor size, Barcelona Clinic Liver Cancer (BCLC), and presence of portal venous thrombosis.

Methods: This cross-sectional study involved 100 patients in Adam Malik General Hospital diagnosed with HCC, collected with a consecutive sampling method, whose diagnosis were confirmed by findings of hypervascular on arterial phase imaging and portal vein or delayed phase washout triple-phase CT Scan. Samples are later categorized according to Barcelona Clinic Liver Cancer (BCLC) stages, tumor size, and presence of portal venous thrombosis. Blood samples were drawn to measure serum Midkine using ELISA. Kruskal-Wallis and Mann-Whitney U tests were conducted to determine the difference of Midkine levels based on tumor size, BCLC staging, and presence of portal venous thrombosis.

Results: Serum Midkine level shows a significant difference over tumor size (p=0.014), no significant difference found compared to BCLC stages and presence of portal venous thrombosis.

Conclusion: Serum Midkine levels are associated with the tumor size of HCC, thus helping physicians determine treatment plans.

Parole chiave

  • Midkine
  • liver neoplasms
  • hepatocellular carcinoma
  • biomarker
  • cytokine
access type Accesso libero

External Validation of the 4C Mortality Score and PRIEST COVID-19 Clinical Severity Score in patients hospitalized with COVID-19 pneumonia in Greece

Pubblicato online: 25 Sep 2022
Pagine: -

Astratto

Abstract

Background: Prognostic scores can be used to facilitate better management of patients suffering from life-threatening diseases, provided that they have been tested in the population of interest.

Aim: To perform external validation of the 4C Mortality Score and PRIEST COVID-19 Clinical Severity Score.

Study Design: Prospective Observational Study.

Methods: Patients hospitalized with COVID-19 pneumonia in a tertiary hospital in Greece were enrolled in the study. The prognostic scores were calculated based on hospital admission data and ROC curve analysis was performed. We assessed a composite outcome of either in-hospital death or need for invasive ventilation.

Results: Both 4C and PRIEST scores showed good discriminative ability with an AUC value of 0.826 (CI 95%: 0.765-0.887) and 0.852 (CI 95%: 0.793-0.910) respectively. Based on the Youden Index the optimal cut-off for the 4C score was 11 (Sensitivity 75%, Specificity 75.5%) and 10 for the PRIEST score (Sensitivity 83% and Specificity 69.4%). Calibration was adequate for both scores, except for the low and very high risk groups in the PRIEST score.

Conclusion: The 4C Mortality Score and PRIEST COVID-19 Clinical Severity Score can be used for early identification of patients with poor prognosis in a Greek population cohort hospitalized with COVID-19.

Parole chiave

  • prognosis
  • risk scores
  • covid-19
  • triage
  • risk assessment

Pianifica la tua conferenza remota con Sciendo